支气管扩张剂是慢阻肺治疗核心.pptVIP

UPLIFT研究：噻托溴铵在原有治疗基础上显著降低不良事件风险，尤其是心血管系统、心肌梗塞和呼吸困难 Tashkin DP et al. N Engl J Med. 2008; 359(15):1543-54. 一项为期4年的随机对照、双盲设计试验中，5993名40岁以上稳定期慢阻肺患者 (mean age, 65+/-8 years with a mean FEV1 of 1.32+/-0.44 liters after bronchodilation 48% of predicted value)被随机分配到噻托溴铵组和安慰剂组，观察慢阻肺全因死亡风险。 *P0.05 噻托溴铵不含ICS，长期安全性良好，是GOLD指南认可的一线支扩剂 Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Revised 2014. Extensive use of this class of inhaled agents in a wide range of doses and clinical settings has shown them to be very safe. 广泛使用的安全性十分良好 However, the findin